SEC Form 4 · accession 0000899243-18-029132
AVEO PHARMACEUTICALS INC · AVEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony B Evnin
Director
Period of report
Nov 14, 2018
Accepted (ET)
Nov 16, 2018 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001325879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 14, 2018 | S | 325,139 | $1.9003 | D | 821,929 | I | By Funds |
| Common StockF4,F5,F3 | Nov 15, 2018 | S | 670,894 | $1.8606 | D | 151,035 | I | By Funds |
| Common StockF6,F7,F3 | Nov 16, 2018 | S | 151,035 | $1.8168 | D | 0 | I | By Funds |
| Common StockF8 | holding | — | — | — | 418,414 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of (a) 58,519 shares of common stock sold by Venrock Associates, or VA, (b) 260,087 shares of common stock sold by Venrock Associates III, L.P., or VA III, (c) 6,502 shares of common stock sold by Venrock Entrepreneurs Fund III, L.P., or VEF III, and (d) 31 shares of common stock sold by VEF Management III, LLC, or VEFM III.
- F2The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.89 to $1.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Dr. Evnin is a General Partner of VA. Venrock Management III, LLC, or VM III, is the sole General Partner of VA III. VEFM III, is the sole General Partner of VEF III. Dr. Evnin is a Member of VM III and VEFM III. Dr. Evnin expressly disclaims beneficial ownership over all shares held by or on behalf of VA, VA III, VEF III, VM III, and VEFM III, except to the extent of his indirect pecuniary interest therein.
- F4Consists of (a) 120,749 shares of common stock sold by VA, (b) 536,665 shares of common stock sold by VA III, (c) 13,416 shares of common stock sold by VEF III, and (d) 64 shares of common stock sold by VEFM III.
- F5The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.85 to $1.875, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6Consists of (a) 27,184 shares of common stock sold by VA, (b) 120,817 shares of common stock sold by VA III, (c) 3,020 shares of common stock sold by VEF III, and (d) 14 shares of common stock sold by VEFM III.
- F7The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.785 to $1.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8None of the shares held directly by Dr. Evnin were sold in these transactions.